Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
Date:2/28/2013

host)

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform inc
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
2. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
3. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
8. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 ... the addition of the  "Global Operating Room ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An ... sterile environment in a healthcare facility used ... with technically advanced equipment, which ensures patient ...
(Date:8/22/2014)... HILL, N.C. , Aug. 22, 2014  As ... the healthcare sector, many leaders in this area are ... The Medical Affairs Consortium at Best ... a forum for sharing insights about the key challenges ... creating and sharing solutions through three virtual roundtable discussions ...
(Date:8/22/2014)...  Dr. Mark Rasak , MD is recognized ... Award in the field of Medicine as a result ... Dr. Rasak has over 15 years of ... the business; overseeing the daily operations; interventional cardiology; complex ... addition, he is an honored Fellow of the American ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... DALLAS, October 28, 2011   ... Analysis and Forecasts to 2020, to its store. This ... US. In addition, it covers detailed clinical assessment of ... analysis of sales performance during the forecast period (2016-2020). ...
... Publicis Groupe announced today that Digitas Health and ... (PHCG), powerfully redefining Publicis Groupe,s client offering to ... PHCG is the world,s leading healthcare communications ... Razorfish Health -- Publicis Groupe,s largest digital agencies ...
Cached Medicine Technology:ReportsnReports - Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020 2ReportsnReports - Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020 3ReportsnReports - Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020 4Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 2Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 3Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 4Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 5
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... to be filed in U.S. courts on behalf ... due to their use of prescription low testosterone ... documents, a new claim was filed against Pfizer ... who allegedly suffered life-threatening heart issues due to ...
(Date:8/22/2014)... Prairie du Sac, Wisconsin (PRWEB) August 22, 2014 ... FasciaDerm® PFTape™ System for Plantar Fasciitis, an exciting new ... The product allows you to stay active while you ... per application. This is truly a new technology – ... patented and affordable. , FasciaDerm® PFTape™ System for ...
(Date:8/22/2014)... August 22, 2014 The improved access ... specifically in the developing world, has led to the ... number of deaths due to AIDS globally. However, despite ... number of new patients becoming affected by the virus ... being undertaken by all related organisations and stakeholders, by ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Back-to-school time provides ... that fits into the family schedules, an expert suggests. ... child,s school year can also be the start of ... Richards, a professor of kinesiology at the University of ... release. With kids, extracurricular activities likely to build ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a ... a $141 million campus renewal. Renderings of ... to the public. , The new patient tower is ... a campus that meets the needs of patients, families and ... will embody Dayton Children’s unique patient care mission and offer ...
Breaking Medicine News(10 mins):Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:With Kids in School, Parents Can Work Out 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... Ultrasound and Management Practice Software to Support Advanced Diagnoses ... ... Oct. 21 South Carolina Veterinary,Specialists (SCVS), a leading regional ... Digital Practice(R) at its,new state-of-the-art facility in Columbia. The Eklin ...
... EXTON, Pa., Oct. 21 Isolagen(TM), Inc. (Amex:,ILE) ... in the Phase,II/III Study IT-A-008 investigating Isolagen Therapy(TM) ... scars. Further, approximately half of all,of the study ... the acne study will conclude in the first ...
... Is Safe And Active in Recurrent Ovarian Cancer; ... Oct. 21 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... results of the company,s proprietary polymer DACH,platinum prodrug, ... this week at a major international oncology conference ...
... reserve compensates for brain damage, study says , , TUESDAY, ... of education and a mentally demanding job may help ... according to an Italian study. , It included 242 ... 144 with no memory problems. People with mild cognitive ...
... players reach the base faster that way , , TUESDAY, Oct. ... slide head first or feet first during Wednesday,s first game ... a physicist instead of a coach. , The effectiveness of ... and factors like a baseball player,s center of gravity, explained ...
... risk, study finds , , TUESDAY, Oct. 21 (HealthDay News) -- ... the first time in a decade, particularly among middle-aged white ... we haven,t had as much focus on in terms of ... males, and there has been a lot of attention to ...
Cached Medicine News:Health News:South Carolina Veterinary Specialists Installs State-of-the-Art Eklin Digital Practice(R) Technology 2Health News:South Carolina Veterinary Specialists Installs State-of-the-Art Eklin Digital Practice(R) Technology 3Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 2Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 3Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 2Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 3Health News:Job, Education May Buffer Against Dementia 2Health News:Head-First Slide a Heads-Up Play 2Health News:Suicide Rates Rise Among Baby Boomers 2Health News:Suicide Rates Rise Among Baby Boomers 3
... Hema-G Stains for Geometric Data ... performance. Stains are quality control ... to ensure proper staining and ... most applications for a minimum ...
Wright Stain Solutions...
... single-solution staining, Hema-Quik for Wright ... stain solution for five to ... water for five to fifteen ... by dipping quickly in deionized ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
Medicine Products: